Search
Stories, the companies and people Loro tracks, and the primary records behind them — filings, donations, contracts and disclosures.
Company or person1
PROCTER & GAMBLE Co
Company
Primary record20
ROBIQUITY LIMITED: ownership and control
ROBIQUITY LIMITED (company 09714317), incorporated 2015-08-03, status active. Current officers: DAVIES, Thomas (director); DE BROISE, Anthony James (director); GROVER, Frederick Philip (director); PROCTER, James (directo
NEW YORK STOCK EXCHANGE LLC filed 25-NSE
0000876661-26-000894.txt : 20261106 25-NSE 1 primary_doc.xml X0203 0000876661 NEW YORK STOCK EXCHANGE LLC 0000080424 PROCTER & GAMBLE Co 001-00434 1 Procter & Gamble Plaza Cincinnati OH OHIO 45202 (513) 983-1100 0.110% N
ROBIQUITY LIMITED: ownership and control
ROBIQUITY LIMITED (company 09714317), incorporated 2015-08-03, status active. Current officers: DAVIES, Thomas (director); DE BROISE, Anthony James (director); GROVER, Frederick Philip (director); PROCTER, James (directo
Avalo Therapeutics, Inc. filed 8-K
Item 1.01 Entry into a Material Definitive Agreement. On November 5, 2026, Avalo Therapeutics, Inc. (the “Company”) entered into an Open Market Sale Agreement SM (the “Jefferies Sales Agreement”), with Jefferies LLC (“Je
PROCTER & GAMBLE Co filed 4
SEC form 4 filed by PROCTER & GAMBLE Co (CIK 80424) on 2026-11-05.
Digital Turbine, Inc. filed 8-K
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (c) Effective as of November 2, 2026, the Board of Directors of
FATE THERAPEUTICS INC filed 8-K
Item 1.01 Entry into a Material Definitive Agreement. On November 5, 2026, Fate Therapeutics, Inc. (the “Company”) entered into a Sales Agreement (the “Sales Agreement”) with Leerink Partners LLC (“Leerink Partners”), wi
ROBIQUITY LIMITED: ownership and control
ROBIQUITY LIMITED (company 09714317), incorporated 2015-08-03, status active. Current officers: DAVIES, Thomas (director); DE BROISE, Anthony James (director); GROVER, Frederick Philip (director); PROCTER, James (directo
PROCTER & GAMBLE Co filed 4
SEC form 4 filed by PROCTER & GAMBLE Co (CIK 80424) on 2026-11-03.
PROCTER & GAMBLE Co filed 4
SEC form 4 filed by PROCTER & GAMBLE Co (CIK 80424) on 2026-11-03.
PROCTER & GAMBLE Co filed 8-K
Item 8.01 Other Events. On November 3, 2026, The Procter & Gamble Company (the “Company”) closed an underwritten public offering of €750,000,000 aggregate principal amount of 3.750% Notes due November 3, 2030, €1,000,000
PROCTER & GAMBLE Co filed 4
SEC form 4 filed by PROCTER & GAMBLE Co (CIK 80424) on 2026-11-03.
PROCTER & GAMBLE Co filed 4
SEC form 4 filed by PROCTER & GAMBLE Co (CIK 80424) on 2026-11-03.
PROCTER & GAMBLE Co filed 8-K
Item 8.01 Other Events. On November 2, 2026, The Procter & Gamble Company (the “Company”) closed an underwritten public offering of $352,231,000 aggregate principal amount of Floating Rate Notes due November 2, 2076 unde
Rapport Therapeutics, Inc. filed 8-K
Item 1.01 Entry into a Material Definitive Agreement. Underwriting Agreement in Respect of Common Stock and Pre-Funded Warrants On October 28, 2026, Rapport Therapeutics, Inc. (the “Company”) entered into an underwriting
PROCTER & GAMBLE Co filed 8-K
Item 8.01 Other Events. On October 30, 2026, The Procter & Gamble Company (the “Company”) closed an underwritten public offering of $750,000,000 aggregate principal amount of 5.125% Notes due October 30, 2031, $750,000,0
CLOROX CO /DE/ filed 8-K
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On October 28, 2026, the Board of Directors (the “Board”) of Th
FIRST FINANCIAL BANCORP /OH/ filed 8-K
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers. (d) On October 27, 2026, the Board of Directors (the “Board”) of
ALIGN TECHNOLOGY INC filed 8-K
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. CEO Succession and Appointment of New Director On October 26, 2
Dogwood Therapeutics, Inc. filed SCHEDULE 13D/A
0001104659-26-119153.txt : 20261027 SCHEDULE 13D/A 1 primary_doc.xml X0202 SCHEDULE 13D/A 0001104659-24-108596 0002040446 XXXXXXXX LIVE 4 Common Stock, $0.0001 par value 10/26/2026 false 0001818844 92829J203 Dogwood Ther